Long-term outcome in cervical lymph node-positive nasopharyngeal carcinoma following IMRT with one-step cervical nodal CTV delineation by geometric-anatomic expansion from nodal GTV: A double-center experience.
{"title":"Long-term outcome in cervical lymph node-positive nasopharyngeal carcinoma following IMRT with one-step cervical nodal CTV delineation by geometric-anatomic expansion from nodal GTV: A double-center experience.","authors":"Qiaojuan Guo, Jing Huang, Nan Xiao, Fangyuan Zhou, Wanfang Huang, Shuhan Zhao, Jihong Chen, Hanchuan Xu, Ziyi Wu, Yahan Zheng, Xinlan Chen, Jianji Pan, Kunyu Yang, Shaojun Lin","doi":"10.1016/j.ijrobp.2024.12.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To report long-term results of cervical node-positive (CLN+) nasopharyngeal carcinoma (NPC) patients treated with IMRT with one-step nodal clinical target volume (CTVn) delineation by geometric-anatomic expansion from the nodal gross target volume (GTVn).</p><p><strong>Materials: </strong>CLN+ NPC treated with the same one-step-CTVn delineation in two Chinese academic centers were pooled for this study. GTVn was prescribed to 70 Gy equivalent, CTVn1 was omitted, CTVn2 was prescribed to 45-55 Gy equivalent and defined as GTVn + 3 mm geometric expansion (5 mm if radiological extranodal extension-positive, rENE+) + elective nodal regions defined by anatomic boundary of cervical nodal levels. Regional-control (RC) and overall survival (OS) were analyzed. Fifteen randomly selected cases were recontoured for CTVn according to 2018 International Guidelines (2018-IG). Dose/volume was compared between the two CTV delineation methods.</p><p><strong>Results: </strong>A total of 807 patients were included (Center 1, n=459; Center 2, n=348). Five-year RC and OS were 95.8% and 86.2%, respectively. Thirty-four patients developed regional failure, and 13/34 (38%) were outside CTVn2: level VIII (parotid node) (9/13), Ib (4/13), and IV (2/13). Seven out of these 9 level VIII failures had preexisting \"equivocal\" nodes. All 4 level 1b failures had \"equivocal\" nodes with very advanced rENE or large (>5 cm) nodal mass in level II. Compared with the 2018-IG, our strategy resulted in significant reduction in nodal volumes received therapeutic (V70) (mean: 100.7 vs 27.5 cc, p<0.001) and prophylactic (V45) (mean: 343.5 vs 261.2 cc, p<0.001) doses, and further dose reduction in surrounding organs-at-risks.</p><p><strong>Conclusion: </strong>Our one-step-CTVn delineation by geometric-anatomic expansion from GTVn appears to be a safe and efficient approach in CLN+ NPC with excellent RC and potential dosimetric benefit in selected patients. Caution is needed for parotid sparing in patients with preexisting \"equivocal\" nodes or level Ib sparing in cases with advanced rENE or large (>5 cm) nodal mass in level II.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.12.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To report long-term results of cervical node-positive (CLN+) nasopharyngeal carcinoma (NPC) patients treated with IMRT with one-step nodal clinical target volume (CTVn) delineation by geometric-anatomic expansion from the nodal gross target volume (GTVn).
Materials: CLN+ NPC treated with the same one-step-CTVn delineation in two Chinese academic centers were pooled for this study. GTVn was prescribed to 70 Gy equivalent, CTVn1 was omitted, CTVn2 was prescribed to 45-55 Gy equivalent and defined as GTVn + 3 mm geometric expansion (5 mm if radiological extranodal extension-positive, rENE+) + elective nodal regions defined by anatomic boundary of cervical nodal levels. Regional-control (RC) and overall survival (OS) were analyzed. Fifteen randomly selected cases were recontoured for CTVn according to 2018 International Guidelines (2018-IG). Dose/volume was compared between the two CTV delineation methods.
Results: A total of 807 patients were included (Center 1, n=459; Center 2, n=348). Five-year RC and OS were 95.8% and 86.2%, respectively. Thirty-four patients developed regional failure, and 13/34 (38%) were outside CTVn2: level VIII (parotid node) (9/13), Ib (4/13), and IV (2/13). Seven out of these 9 level VIII failures had preexisting "equivocal" nodes. All 4 level 1b failures had "equivocal" nodes with very advanced rENE or large (>5 cm) nodal mass in level II. Compared with the 2018-IG, our strategy resulted in significant reduction in nodal volumes received therapeutic (V70) (mean: 100.7 vs 27.5 cc, p<0.001) and prophylactic (V45) (mean: 343.5 vs 261.2 cc, p<0.001) doses, and further dose reduction in surrounding organs-at-risks.
Conclusion: Our one-step-CTVn delineation by geometric-anatomic expansion from GTVn appears to be a safe and efficient approach in CLN+ NPC with excellent RC and potential dosimetric benefit in selected patients. Caution is needed for parotid sparing in patients with preexisting "equivocal" nodes or level Ib sparing in cases with advanced rENE or large (>5 cm) nodal mass in level II.
期刊介绍：
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
